Cardiac Webinars

Natriuretic Peptides (BNP /NT-proBNP)

Utility of Natriuretic Peptides in the Era of Emerging Heart Failure Therapies


Professor Alexandre Mebazaa, MD, PhD: Chairman of the Department of Anesthesia and Critical Care, Saint-Louis and Lariboisiere Hospitals- Paris France

Professor Kenneth McDonald, MD: Director, Heart Failure Service St. Vincent’s Healthcare Group- Dublin, Ireland

Professor Alan S. Maisel, MD: Director, Coronary Care Unit and Heart Failure Program, Veterans Affairs San Diego Healthcare System- California, United States

Natriuretic peptides have long played a useful role in the management of heart failure patients. However, their utility with emerging heart failure therapies remains to be fully elucidated. Will this utility change? Will natriuretic peptide values show the same trends in terms of outcomes? What mechanisms underlie the interplay between natriuretic peptides and these new therapies?

About Dr. Alexandre Mebazaa

Professor Alexandre Mebazaa is Chairman of the Department of Anesthesia and Critical Care, Saint-Louis & Lariboisiere Hospitals in Paris. His research interests include global studies on biomarkers in acute heart failure and mechanisms of contractile impairment during acute heart failure. Prof. Mebazaa has authored and co-authored more than 200 papers and is Lead Editor of the Acute Heart Failure textbook. He acted as Chair or member of several Steering Committees including SURVIVE, COMPOSE, and TRUE-HF and is also involved in several European and global registries on circulatory failure.

About Dr. Kenneth McDonald

Professor Kenneth McDonald is recognized globally for his expertise in cardiovascular biomarker research and clinical management in heart failure. He has carried out pioneering research in the field of heart failure, developing the St. Vincent’s Screening to Prevent Failure (STOP-HF) project, the results of which were published in JAMA. Prof McDonald is a Health Research board Clinical Scientist and has authored or co-authored more than 250 papers and abstracts in peer-reviewed journals. He continues full-time clinical commitment to the care of patients with heart failure while serving as National Director for the Heart Failure Clinical Program in Ireland and President of the Irish Cardiac Society.

About Dr. Alan Maisel

Professor Alan Maisel is considered one of the world’s experts on cardiac biomarkers and has over 400 scientific publications. He has authored several ground-breaking manuscripts that have paved the way for development of diagnostics tools for patients with heart failure and the leading investigator on studies that brought the use of BNP into clinical practice. Prof. Maisel was lead investigator on seven multicenter biomarker trials, co-founded the UCSD Biomarker Research Center and just completed ten years as Associated Editor of the Journal of the American College of Cardiology. He is Director of the Coronary Care Unit and Heart Failure Program at the VA San Diego Healthcare System.

Learning Objectives

  • Understand natriuretic peptide metabolic pathways
  • Learn about the utility of natriuretic peptides in heart failure
  • Comprehend the potential implications of emerging therapies on natriuretic peptides

Who Should Attend

  • Laboratorians
  • Cardiologists
  • Heart Failure Specialists
  • Heart Failure Nurses
  • Pharmacists                  
September 22, 2015

Galectin-3: A Step Towards a Clearer Pathway in Heart Failure Management

Author: Peter McCullough, MD, MPH, FACC, FACP, FCCP, FAHA, FNKF, FNLA Cardiologist at Baylor Heart and Vascular Institute

There have been significant advances in heart failure diagnosis, management, and treatment, but there is still a need for new tools to help optimize the management of this healthcare burden. Recently, novel biomarkers have emerged as additional tools to aid in prognosis and management of heart failure. During today's webcast, we will learn about a new and emerging biomarker called Galectin-3 and how it can be used as a management tool for heart failure patients.

About Dr. Peter McCullough

After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough directs cardiovascular education and research for the Baylor Health Care System and is a Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX and is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications including the "Interface between Renal Disease and Cardiovascular Illness" in Braunwald's Heart Disease Textbook.

In 2013, he was honored with the International Vicenza Award for Critical Care Nephrology for his outstanding contribution and dedication to the emerging problem of cardiorenal syndromes. Dr. McCullough is the current Chair of the National Kidney Foundation's Kidney Early Evaluation Program (KEEP), the nation's largest community screening effort for chronic diseases. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, and other top-tier journals worldwide. He is the co-editor of Reviews in Cardiovascular Medicine and serves on the editorial boards of multiple specialty journals.

Major Contributions:

  • Senior leadership and oversight of clinical, education, and research operations at major academic medical centers
  • Clinical development of in vitro diagnostic assays for heart and kidney disease now used worldwide
  • Editor and Chairman, KEEP Annual Data Report published in the American Journal of Kidney Disease
  • Observational studies and randomized trials of therapies for acute kidney injury, hypertension, acute coronary syndromes, heart failure, and cardiorenal syndromes
  • Board certification in internal medicine, cardiology, clinical lipidology, and echocardiography with a practice dedicated to the prevention and treatment of common diseases including obesity, diabetes, kidney and heart disease

Learning Objectives:

  •  Understand what Galectin-3 is
  • Learn about pathophysiology of cardiac fibrosis and the role of Galectin-3
  • Comprehend how Galectin-3 can be used as a management tool for heart failure patients

Who Should Attend: 

  • Laboratorians
  • Heart failure nurses
  • Heart failure specialists
  • Cardiologists
  • Emergency Physicians
additional webinars



infectious disease webinars

View webinars on Infectious Disease.


You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No


Content is not under the control of

Yes No